Expressions of VEGF and Its Receptors in Rat Corpus Luteum during Interferon Alpha Administration in Early and Pseudopregnancy

Molecular Reproduction and Development

Volumn 67, Issue 4, 2004, Pages 414-423

  Celik Ozenci, Ciler ^a   Akkoyunlu, Gokhan ^a   Korgun, Emin Turkay ^a   Savas, Burhan ^a   Demir, Ramazan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; Corpus luteum; Interferon alpha; Receptors; VEGF

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CD34 ANTIGEN; RECOMBINANT ALPHA2B INTERFERON; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BASAL BODY TEMPERATURE; CANCER INHIBITION; CELL FUNCTION; CONTROLLED STUDY; CORPUS LUTEUM; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; LUTEAL CELL; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PSEUDOPREGNANCY; RAT; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CORPUS LUTEUM; FEMALE; GENE EXPRESSION REGULATION; GONADOTROPINS; HORSES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; PREGNANCY; PREGNANCY, ANIMAL; PSEUDOPREGNANCY; RATS; RATS, WISTAR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1542316748     PISSN: 1040452X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrd.20001     Document Type: Article

References (30)

1. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD. 1985. Intraperitoneal recombinant ápha-interferon for salvage immunotherapy in stage III epithelial ovarian cancer: A gynecologic oncology group study. Cancer Res 45:4447-4453.
2. National Cancer Institute. 2003. News and features. Angiogensis inhibitors in clinical trials. http://cancertrials.nci.nih.gov/news/angio/table.html.
3. Chen YJ, Feng Q, Liu YX. 1999. Expression of the steroidogenic acute regulatory protein and luteinizing hormone receptor and their regulation by tumor necrosis factor alpha in rat corpora lutea. Biol Reprod 60:419-427.
4. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085.
5. Demir R, Kaufmann P, Castellucci M, Erbengi T, Kotowski A. 1989. Fetal vasculogenesis and angiogenesis in human placental villi. Acta Anat (Basel) 136:190-203.
6. Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocr Rev 18:4-25.
7. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH. 1998. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336-340.
8. Folkman J. 1992. Tumor angiogenesis. In: Holland et al., (Eds.). Cancer medicine. Hamilton, Ontario, Canada: B.C. Decker, Inc.
9. Fraser HM, Dickson SE, Morris KD, Erickson GF, Lunn SF. 1999. The effect of the angiogenesis inhibitor TNP-470 on luteal establishment and function in the primate. Hum Reprod 14:2054-2060.
10. Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA, Bicknell R. 2000. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141:995-1000.
11. Hanahan D. 1997. Signaling vascular morphogenesis and maintenance. Science 277:48-50.
12. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
13. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
14. Hazzard TM, Rohan RM, Molskness TA, Fanton JW, D'Amato RJ, Stouffer RL. 2002a. Injection of antiangiogenic agents into the macaque preovulatory follicle: Disruption of corpus luteum development and function. Endocrine 17:199-206.
15. Hazzard TM, Xu F, Stouffer RL. 2002b. Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys. Biol Reprod 67:1305-1312.
16. Jayalitak PG, Glasser LA, Warshaw ML, Herz Z, Gruber JR, Gibori G. 1984. Relationship between luteinizing hormone and decidual luteotropin in the maintenance of luteal steroidogenesis. Biol reprod 31:556-564.
17. Kashida S, Sugino N, Takiguchi S, Karube A, Takayama H, Yamagata Y, Nakamura Y, Kato H. 2001. Regulation and role of vascular endothelial growth factor in the corpus luteum during mid-pregnancy in rats. Biol Reprod 64:317-323.
18. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. 1996. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial Est 1684. J Clin Oncol 14:7-17.
19. Klauber N, Rohan RM, Flynn E, D'Amato RJ. 1997. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 3:443-446.
20. Koos RD. 1995. Increased expression of vascular endothelial growth/permeability factor in the rat ovary following an ovulatory gonadotropin stimulus: Potential roles in follicle rupture. Biol Reprod 52:1426-1435.
21. Lee A, Christenson LK, Patton PE, Burry KA, Stouffer RL. 1997. Vascular endothelial growth factor production by human luteinized granulosa cells in vitro. Hum Reprod 12:2756-2761.
22. Marshall ME, Wolf M, Crawford ED, Thompson IM, Flanigan R, Balcerzak SP, Meyers FJ. 1995. Evaluation of low dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: A southwest oncology group study. Cancer Biother 10:205-209.
23. Masferrer JL, Koki A, Seibert K. 1999. COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci 889:84-86.
24. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. 1994. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269:25646-25654.
25. Senturk LM, Seli E, Gutierrez LS, Mor G, Zeyneloglu HB, Arici A. 1999. Monocyte chemotactic protein-1 expression in human corpus luteum. Mol Hum Reprod 5:697-702.
26. Shepherd FA, Beaulieu R, Gelmon K, Thuot CA, Sawka C, Read S, Singer J. 1998. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV clinical trials network study. J Clin Oncol 16:1736-1742.
27. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. 1995. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92:4562-4566.
28. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. 1999. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726-2734.
29. Sugino N, Kashida S, Takiguchi S, Karube A, Kato H. 2000. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. J Clin Endocrinol Metab 85:3919-3924.
30. Tamura H, Greenwald GS. 1987. Angiogenesis and its hormonal control in the corpus luteum of the pregnant rat. Biol Reprod 36:1149-1154.